ROCKetTheranova 400 Dialyseur vs. HDF chez les patients atteints d'insuffisance rénale sous hémodialyse

This study focuses on kidney failure patients who are undergoing hemodialysis. The main goal is to compare the effectiveness of a new type of dialyzer, Theranova 400, with the current hemodiafiltration (HDF) treatment. The study aims to improve the clearance of larger toxins that traditional hemodialysis cannot effectively remove. These toxins may lead to inflammation, atherosclerosis, and calcification, which can indirectly cause patient death. Theranova 400, with its innovative Medium Cut-Off® membranes, promises better clearance of these toxins while retaining essential proteins, offering a potential improvement in care for kidney failure patients on hemodialysis. During the study, participants will undergo dialysis sessions using either the Theranova 400 dialyzer or the current HDF treatment. The effectiveness of each treatment will be measured by the reduction ratio of specific toxins, Beta-2 Microglobulin (β2-MG) and Lambda Free Light Chains (λ FLC), in the blood before and after the dialysis session. The reduction ratio is calculated by subtracting the post-dialysis toxin level from the pre-dialysis level, then dividing by the pre-dialysis level. This study hopes to demonstrate that the Theranova 400 dialyzer is not inferior to the current HDF treatment in terms of toxin clearance.